Nanobiotix Q3 Update Highlights Strategic Moves: Phase 3 Head And Neck Cancer Trial Transferred To Janssen, Curadigm Platform Expansion; €53.2M Cash Reserves

Benzinga11/12 15:58

Press Release: NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Dow Jones11/12 15:30

NANOBIOTIX to Participate in Multiple Investor Conferences in November

GlobeNewswire10/31 15:30

Nanobiotix H1 Loss Narrows, Revenue Rises

MT Newswires09/19 05:18

NANOBIOTIX Expects Cash And Equivalents Of €66.3M As Of June-End, To Now Fund Operations Into Q4 2025, Compared To Q3 2025 In Prior Guidance

Benzinga09/19 04:21

Nanobiotix 1H Loss/Shr EUR0.46 >NANO.FR

Dow Jones09/19 04:20